NCT03766724 - Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 22, 2018

Primary Completion Date

January 18, 2019

Study Completion Date

January 18, 2019

Conditions

Type2 Diabetes

Interventions

DRUG

Evogliptin→Evogliptin+Empagliflozin→Empagliflozin

Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD

DRUG

Empagliflozin→Evogliptin→Evogliptin+Empagliflozin

Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD

DRUG

Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin

Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD

DRUG

Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin

Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD

Trial Locations (1)

Clinical Trials Center, Severance Hospital, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY